Lawmakers demand study data on Vytorin cancer risk
Lawmakers demand study data on Vytorin cancer risk Save Email Print
Posted: 7:07 PM Aug 21, 2008
Last Updated: 10:29 PM Sep 4, 2008

A | A | A

TRENTON, N.J. (AP) -- A congressional committee is giving the two makers of the cholesterol drug Vytorin two weeks to produce extensive data on a clinical study indicating the drug might increase the risk of cancer.

The FDA says it expects a final report in about three months, and would need another six months to fully evaluate the information. It also says patients should not stop taking Vytorin or other cholesterol drugs in the meantime.

But two Democratic congressmen are demanding information on all financial and other ties between Merck and Schering-Plough and British scientists who are running another study of the controversial drug.

The companies, which have a lucrative joint venture selling cholesterol drugs, say they've received the congressmen's letter and "are cooperating fully with the committee."

(Copyright 2008 by The Associated Press. All Rights Reserved.)

More Stories
How safe and effective are sunscreens?

Tennessee labs test for more disease than normal

HPV vaccine for men?

Volunteering for medical research

New HIV map finds cases heavy in the South

FDA says Zicam nasal spray can cause loss of smell

Local healthcare reform debate

WHO raising H1N1 flu alert to highest level.

Post Your Comments
First Name:
Location:
Enter Comments: characters left
Email (optional):
By posting this comment I have read and agree to the Terms of Use and Privacy Policy:
You must agree to the Terms of Service to continue.
Currently
Local Radar
Radar